Johannes Kullmer
Overview
Explore the profile of Johannes Kullmer including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
294
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ruhnke L, Bill M, Zukunft S, Eckardt J, Schafer S, Stasik S, et al.
Blood Adv
. 2024 Nov;
PMID: 39504561
In 2022, the European LeukemiaNet (ELN) risk stratification for patients with AML has been updated. We aimed to validate the prognostic value of the 2022 ELN classification (ELN22) evaluating 1,570...
2.
Baden D, Zukunft S, Hernandez G, Wolgast N, Steinhauser S, Pohlmann A, et al.
Haematologica
. 2024 Apr;
109(8):2469-2477.
PMID: 38654660
In newly diagnosed acute myeloid leukemia (AML), immediate initiation of treatment is standard of care. However, deferral of antileukemic therapy may be indicated to assess comorbidities or pretherapeutic risk factors....
3.
Hanoun M, Ruhnke L, Kramer M, Hanoun C, Schafer-Eckart K, Steffen B, et al.
J Cancer Res Clin Oncol
. 2022 Sep;
149(8):4611-4621.
PMID: 36167894
Purpose: Higher doses of cytarabine appear to improve long-term outcome in acute myeloid leukemia (AML), in particular for younger patients. To this end, the optimal dosage of single-agent cytarabine in...
4.
Rollig C, Serve H, Noppeney R, Hanoun M, Krug U, Baldus C, et al.
Leukemia
. 2021 Feb;
35(9):2517-2525.
PMID: 33603142
Early results of the randomized placebo-controlled SORAML trial showed that, in patients with newly diagnosed acute myeloid leukaemia (AML), sorafenib led to a significant improvement in event-free (EFS) and relapse-free...
5.
Rollig C, Kramer M, Schliemann C, Mikesch J, Steffen B, Kramer A, et al.
Blood
. 2020 Jun;
136(7):823-830.
PMID: 32496541
In fit patients with newly diagnosed acute myeloid leukemia (AML), immediate treatment start is recommended due to the poor prognosis of untreated acute leukemia. We explored the relationship between time...
6.
Rollig C, Serve H, Huttmann A, Noppeney R, Muller-Tidow C, Krug U, et al.
Lancet Oncol
. 2015 Nov;
16(16):1691-9.
PMID: 26549589
Background: Preclinical data and results from non-randomised trials suggest that the multikinase inhibitor sorafenib might be an effective drug for the treatment of acute myeloid leukaemia. We investigated the efficacy...